menu

CME: Increasing Awareness and Access to Spinal Muscular Atrophy Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Increasing Awareness and Access to Spinal Muscular Atrophy Therapy

Program Information
Recommended
Increasing Awareness and Access to Spinal Muscular Atrophy Therapy
RestartResume
Since there are many types of SMA that differ in age of onset and severity of muscle weakness, how can we identify and treat these patients sooner?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Spinal muscular atrophy (SMA) is a genetic disorder characterized by weakness in muscles and is caused by a loss of specialized nerve cells, called motor neurons, that control muscle movement. Since SMA significantly impacts both the quality of life and lifespan of those affected, this activity will describe the genetic basis for SMA and the various phenotypic expressions as well as improvements in accessing pharmacologic treatments for SMA.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:  
    John F. Brandsema, MD
    Neuromuscular Section Head
    Children’s Hospital of Philadelphia
    Philadelphia, PA

    Consulting Fees: Avexis, Biogen                                                             
    Commercial Interest Speakers Bureau: Biogen                                                     
    Contracted Research: Alexion Pharmaceuticals, Avexis, Biogen, Cytokinetics, Fibrogen, Pfizer, PIC, Sarepta Therapeutics, Summit Pharmaceuticals, WAVE

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the genetic basis for SMA and understand its varied phenotypic expressions that impact the quality of life and lifespan of those affected.
    • Formulate strategies for patients affected by SMA that improve access to pharmacologic treatment for SMA.
  • Target Audience

    This activity is designed to meet the educational needs of neurologists, pulmonologists, pediatricians, primary care physicians and other healthcare professionals who diagnose and care for patients with SMA.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

      

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Biogen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/9/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.